Repeal Tax on Medical Innovation

Tuesday, November 28, 2017

Imagine a young child named Sam, maybe five or six years old, with big eyes, a broad smile, and three big goals: 1) to be a firefighter someday; 2) to go snowboarding with his cousins; and 3) to find a cure for the disease that makes his first two goals an impossibility.

Goals 1 and 2 are impossible because this little boy has the most deadly form of epidermolysis bullosa or EB, a rare disease in which cells lack the protein needed for layers of skin to adhere. His skin is as fragile as a butterfly’s wing, shearing off at the slightest physical contact. He faces hours of brutally painful wound care and bandaging each day, a buffer — albeit an inadequate one — against life-threatening infection. Over time, Sam will lose limb function as scar tissue binds. He will live with relentless pain and die far too young. Researchers are working hard to help these kids, but there is as yet no treatment or cure.

Now imagine a medical device that can literally transform damaged cells into healthy ones, eviscerating health conditions that have eluded answers for years. Researchers at Ohio State University have successfully used Tissue Nanotransfection Technology to reprogram injured cells in mice; human clinical trials are slated to begin next year.

While TNT is promising, it may or may not pan out. Medical progress is a long and winding — not to mention bumpy and expensive – road. Another caveat: to this author’s knowledge, TNT is not being tested for use in EB — yet. But it signifies hope. It offers new possibilities. We may be that much closer to delivering children from a disease that terrorizes them. That’s strong language, but it does not serve our nation to soft-pedal the impact of illnesses like EB. Acute suffering is acute suffering, whether perpetrated by an enemy or an illness.

The moral of the story is this: It matters whether our nation encourages or discourages investment in the R&D that underlies new medical devices like TNT.

Why is it important to acknowledge the value of this R&D now? Because two years ago, Congress acted on a bipartisan basis to suspend an excise tax that had been imposed on medical devices. Unless the current Congress acts to prevent it, the suspension will end and this tax will come back, full force, on Jan. 1, 2018.

That would be a mistake for our nation. The device tax selectively disincentivizes investment in new medical devices, even though these devices mean new jobs, new businesses and new exports.

Read the full op-ed at https://morningconsult.com/opinions/repeal-tax-on-medical-innovation/

Media Contacts

Suzanne Ffolkes
VP Communications
571-482-2710

Anna Briseño
Senior Manager of Communications
571-482-2737

The capabilities are enormous, a little bit of research can pay off quite a bit in the long run.
Paul D’ Addario, retinitis pigmentosa patient